This approach led to disease amelioration in murine experimental autoimmune encephalomyelitis exacerbated by the administration of patient-derived myelin oligodendrocyte glycoprotein-specific antibodies, without affecting antibodies with other antigen specificities [60]. Here, OMG is linked to experimental autoimmune encephalomyelitis.